Ldl Cholesterol
Most patients at high CV risk are not achieving LDL goals
NEW ORLEANS — Most patients at high or very high CV risk do not achieve guideline-recommended LDL goals, according to data from the Family Heart Database presented at the American College of Cardiology Scientific Session.
Navigating the Diagnosis and Treatment of Patients with Narcolepsy and Cardiovascular Risk
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Making Sense of LDL-C Combination Therapy in 2022: Strategies and Pearls to Move Beyond Inertia to Improve Patient Outcomes
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Oral PCSK9 inhibitor lowers LDL similar to injection in short-term phase 2 trial
NEW ORLEANS — In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session.
Causal AI ‘translates’ CAD polygenic risk score into clinically actionable data
NEW ORLEANS — Causal artificial intelligence used to augment a polygenic risk score for CAD helped estimate how much individual patients must lower their LDL, systolic BP or both to overcome inherited risk for a major coronary event.
What You Need to Know About Optimizing Cardiorenal Outcomes with Novel NonSteroidal MRAs
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Escaping the Current Gaps in the Understanding and Treatment of CKD Anemia: Making Sense of Emerging Therapies
Supported by an educational grant from GSK
The Disproportionate Burden of Heart Failure in Women: Advances & Expert Perspectives to Improve Diagnosis & Treatment
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives
Supported by an educational grant from Novo Nordisk
Lectin-like oxidized LDL receptor-1 inhibition safe in patients with diabetes
A novel agent demonstrated a dose-dependent relationship with lectin-like oxidized LDL receptor-1 suppression, a mechanism to lower inflammatory and lipid risk, and was well tolerated in a small study of patients with type 2 diabetes.